Managing oral anticoagulation requires expert experience and clinical evidence

被引:16
作者
Spyropoulos, AC [1 ]
机构
[1] Lovelace Sandia Hlth Syst, Clin Thrombosis Ctr, Albuquerque, NM 87108 USA
关键词
oral anticoagulant therapy; Vitamin K antagonist; warfarin;
D O I
10.1007/s11239-006-5583-8
中图分类号
R5 [内科学];
学科分类号
1002 [临床医学]; 100201 [内科学];
摘要
The management of patients on chronic oral anticoagulant therapy, namely Vitamin K antagonists such as warfarin, is often associated with difficult and challenging issues for the healthcare practitioner. Many of these issues, such as warfarin failure or resistance, the optimal warfarin initiation dose, the optimal target International Normalized Ratio in antiphospholipid syndrome, the optimal monitoring frequency and use of point-of-care monitoring, the management of oral anticoagulation during invasive procedures, and the management of over-anticoagulation, have not been evaluated in rigorously-designed clinical trials. The latest American College of Chest Physician recommendations concerning these issues are Grade 2C, the weakest recommendations available. It remains up to the experience and expertise of the individual practitioner along with whatever clinical evidence is available in a particular healthcare environment-especially one associated with an anticoagulant management service-to implement management strategies with respect to these issues in patients on oral anticoagulation.
引用
收藏
页码:91 / 94
页数:4
相关论文
共 20 条
[1]
A randomized trial comparing 1 mg of oral vitamin K with no treatment in the management of warfarin-associated coagulopathy in patients with mechanical heart valves [J].
Ageno, W ;
Garcia, D ;
Silingardi, M ;
Galli, M ;
Crowther, M .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2005, 46 (04) :732-733
[2]
Antithrombotic and thrombolytic therapy for ischemic stroke [J].
Albers, GW ;
Amarenco, P ;
Easton, JD ;
Sacco, RL ;
Teal, P .
CHEST, 2004, 126 (03) :483S-512S
[3]
The pharmacology and management of the vitamin K antagonists [J].
Ansell, J ;
Hirsh, J ;
Poller, L ;
Bussey, H ;
Jacobson, A ;
Hylek, E .
CHEST, 2004, 126 (03) :204S-233S
[4]
LONG-TERM PATIENT SELF-MANAGEMENT OF ORAL ANTICOAGULATION [J].
ANSELL, JE ;
PATEL, N ;
OSTROVSKY, D ;
NOZZOLILLO, E ;
PETERSON, AM ;
FISH, L .
ARCHIVES OF INTERNAL MEDICINE, 1995, 155 (20) :2185-2189
[5]
Antithrombotic therapy for venous thromboembolic disease [J].
Büller, HR ;
Agnelli, G ;
Hull, RD ;
Hyers, TA ;
Prins, AH ;
Raskob, GE .
CHEST, 2004, 126 (03) :401S-428S
[6]
A comparison of two intensities of warfarin for the prevention of recurrent thrombosis in patients with the antiphospholipid antibody syndrome [J].
Crowther, MA ;
Ginsberg, JS ;
Julian, J ;
Denburg, J ;
Hirsh, J ;
Douketis, J ;
Laskin, C ;
Fortin, P ;
Anderson, D ;
Kearon, C ;
Clarke, A ;
Geerts, W ;
Forgie, M ;
Green, D ;
Costantini, L ;
Yacura, W ;
Wilson, S ;
Gent, M ;
Kovacs, MJ .
NEW ENGLAND JOURNAL OF MEDICINE, 2003, 349 (12) :1133-1138
[7]
A randomized trial comparing 5-mg and 10-mg warfarin loading doses [J].
Crowther, MA ;
Ginsberg, JB ;
Kearon, C ;
Harrison, L ;
Johnson, J ;
Massicotte, P ;
Hirsh, J .
ARCHIVES OF INTERNAL MEDICINE, 1999, 159 (01) :46-48
[8]
Treatment of warfarin-associated coagulopathy with oral vitamin K: a randomised controlled trial [J].
Crowther, MA ;
Julian, J ;
McCarty, D ;
Douketis, J ;
Kovacs, M ;
Biagoni, L ;
Schnurr, T ;
McGinnis, J ;
Gent, M ;
Hirsh, J ;
Ginsberg, J .
LANCET, 2000, 356 (9241) :1551-1553
[9]
Applying the grades of recommendation for antithrombotic and thrombolytic therapy -: The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy [J].
Guyatt, G ;
Schünemann, HJ ;
Cook, D ;
Jaeschke, R ;
Pauker, S .
CHEST, 2004, 126 (03) :179S-187S
[10]
Pharmacodynamic resistance to warfarin associated with a Val66Met substitution in vitamin K epoxide reductase complex subunit I [J].
Harrington, DJ ;
Underwood, S ;
Morse, C ;
Shearer, MJ ;
Tuddenham, EGD ;
Mumford, AD .
THROMBOSIS AND HAEMOSTASIS, 2005, 93 (01) :23-26